Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.6348
+0.0453 (7.68%)
At close: Oct 23, 2025, 4:00 PM EDT
0.6251
-0.0097 (-1.53%)
After-hours: Oct 23, 2025, 7:59 PM EDT
Plus Therapeutics Revenue
Plus Therapeutics had revenue of $1.39M in the quarter ending June 30, 2025, with 8.68% growth. This brings the company's revenue in the last twelve months to $5.32M, down -3.49% year-over-year. In the year 2024, Plus Therapeutics had annual revenue of $5.82M with 18.54% growth.
Revenue (ttm)
$5.32M
Revenue Growth
-3.49%
P/S Ratio
1.93
Revenue / Employee
$253,190
Employees
21
Market Cap
63.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.82M | 911.00K | 18.54% |
| Dec 31, 2023 | 4.91M | 4.69M | 2,093.30% |
| Dec 31, 2022 | 224.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 303.00K | -6.70M | -95.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PSTV News
- 2 days ago - Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory - GlobeNewsWire
- 7 weeks ago - Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria - GlobeNewsWire
- 2 months ago - Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire
- 2 months ago - Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - GlobeNewsWire